DFN-02, Sumatriptan 10 mg Nasal Spray with Permeation Enhancer, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Study Assessing Functional Disability and Subject Satisfaction with Treatment

ConclusionDFN-02 was superior to placebo for the relief of migraine-related functional disability, and provided greater satisfaction than placebo or subjects ’ usual acute treatment.Trial RegistrationClinicalTrials.gov identifier: NCT02856802.

http://link.springer.com/10.1007/s40263-019-00614-6

Source: CNS Drugs - March 14, 2019 Category: Neurology Source Type: research